NCT03566043 - CAMPSIITE™ RGX-121 Gene Therapy in Subjects With MPS II (Hunter Syndrome) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 27, 2018

Primary Completion Date

November 27, 2023

Study Completion Date

August 31, 2025

Conditions

Mucopolysaccharidosis Type II (MPS II)

Interventions

GENETIC

RGX-121

Recombinant adeno-associated virus serotype 9 capsid containing human iduronate-2-sulfatase expression cassette

Trial Locations (5)

Children's Hospital of Pittsburgh - UPMC: Program for Neurodevelopment in Rare Disorders, Pittsburgh

Children's Hospital of Philadelphia, Philadelphia

University of California San Francisco, Benioff Children's Hospital, Oakland

St. Peter's University Hospital, New Brunswick

Hospital de Clinicas de Porto Alegre, Porto Alegre

All Listed Sponsors

lead

REGENXBIO Inc.

INDUSTRY